Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Genakumab in CTD-associated Interstitial Lung Disease
NCT06189495Phase 2Recruiting
- Sponsor
- Changchun GeneScience Pharmaceutical Co., Ltd.
- Start
- Dec 2023
- Primary completion
- Mar 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of genakumab in connective tissue disease-associated interstitial lung disease (CTD-ILD), sponsored by Changchun GeneScience Pharmaceutical Co., Ltd.. Started Dec 2023; status: recruiting.
02
Drugs
genakumab
03
Conditions
connective tissue disease-associated interstitial lung disease (CTD-ILD)
Beyond the preview
Go deeper on NCT06189495.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06189495.